Search
News
RxSight Q2 2026 Earnings: Alcon Revenue Offsets a 19% Product Sales Decline
RxSight’s Q2 2026 revenue was $33.7 million, essentially flat versus $33.6 million a year earlier, while diluted EPS remained a loss of $0.29. The result included $6.5 million of high-margin Alcon collaboration revenue, as product sales fell 19% to $27.2 million amid competitive trialing and weaker consumer sentiment. Total gross margin rose to 76.7%, but product gross margin declined to 71.2%. RxSight ended June with $208.8 million in cash and short-term investments and withdrew its 2026 guidance during a leadership transition and business review.
TradingKey
Wed, Aug 5
Cytek Q2 2026 Earnings: Revenue Rose 6% as Losses Widened
Cytek Biosciences’ Q2 2026 revenue rose 6% year over year to $48.1 million, while GAAP gross margin increased to 59% and diluted loss per share widened to $0.09 from $0.04. A one-time tariff refund accounted for six percentage points of reported margin. Instrument growth in the U.S. and China and expanding service revenue supported sales, but operating expenses increased 15% and adjusted EBITDA turned to a $1.5 million loss. Cytek updated full-year revenue guidance to $207 million-$212 million, raising the midpoint by $1 million.
TradingKey
Wed, Aug 5
ADMA Biologics Q2 2026 Earnings: ASCENIV Mix Drives Margin Expansion
ADMA Biologics’ Q2 2026 revenue rose 2% year over year to $124.4 million, while diluted EPS increased to $0.16 from $0.14. ASCENIV revenue grew 23.5% to $102.9 million and pushed gross margin to 69% from 55%, offsetting a 48.5% decline in BIVIGAM revenue. GAAP net income increased 11% to $37.8 million, adjusted EBITDA reached $61.8 million, and first-half operating cash flow improved to $87.8 million. ADMA reiterated its FY2026 guidance despite continued competitive and pricing pressure in the U.S. immune globulin market.
TradingKey
Wed, Aug 5
Oportun Q2 2026 Earnings: Lower Funding Costs Lift Profit on Flat Revenue
Oportun’s Q2 2026 results showed flat revenue but higher profitability. The consumer lender generated $233.2 million of revenue, compared with $234.3 million a year earlier, while GAAP net income rose 24% to $8.5 million and diluted EPS increased to $0.17. Adjusted EBITDA climbed 56% to $48.6 million as interest expense and operating costs declined. Originations grew 1%, and 30-plus-day delinquencies improved to 4.0%. The key question is whether better credit performance can sustain margins as the owned loan balance remains slightly lower year over year.
TradingKey
Wed, Aug 5
FTAI Infrastructure Q2 2026 earnings: Growth was offset by impairment and interest costs
FTAI Infrastructure (NASDAQ: FIP) reported Q2 2026 revenue of $186.8 million, up about 52.7% year over year, and adjusted EBITDA of $76.1 million versus $45.9 million. Yet net loss attributable to common stockholders widened to $166.5 million, or $1.41 per diluted share, as asset impairment reached $63.2 million and interest expense rose to $105.5 million. Railroad led the four core segments, while the pending Long Ridge sale could eliminate $1.16 billion of project debt and fund approximately $300 million of other debt repayment if regulatory approval is obtained.
TradingKey
Wed, Aug 5
CoreCivic Q2 2026 Earnings: Facility Activations Drive 27.3% Revenue Growth
CoreCivic’s Q2 2026 revenue rose 27.3% to $684.9 million as previously idle facilities were activated and federal and state populations increased. Diluted EPS increased 5.7% to $0.37, while net income declined 3.6% to $37.1 million because the comparison included prior-year Employee Retention Credits and current interest costs were higher. Adjusted EBITDA grew 5.9% to $109.4 million. After quarter-end, four facility sales for $2.2 billion reshaped 2026 guidance, debt reduction plans, and capital allocation, although CoreCivic expects to continue managing those properties under ICE contracts.
TradingKey
Wed, Aug 5
Black Hills Q2 2026 Earnings: Rate Recovery Lifts Adjusted EPS
Black Hills Corp. (NYSE: BKH) reported Q2 2026 revenue of $452.8 million, up 3.1% year over year, and diluted GAAP EPS of $0.50 versus $0.38. Adjusted EPS rose to $0.54 as new rates and rider recovery lifted electric and gas utility operating income, more than offsetting higher depreciation and financing costs. Operating income increased to $97.0 million, while the company reaffirmed 2026 adjusted EPS guidance of $4.25 to $4.45. Wyoming large-load demand and the pending NorthWestern Energy merger remain central items to monitor.
TradingKey
Wed, Aug 5
Lightbridge Q2 2026 earnings: R&D spending widens the net loss
Lightbridge’s fiscal Q2 2026 revenue remained at zero, while its net loss widened to $5.8 million from $3.5 million and loss per share increased to $0.18 from $0.16. R&D expense rose to $3.9 million as compensation, project development and Idaho National Laboratory work increased. At June 30, cash and cash equivalents reached $237.5 million, supported by $43.9 million of first-half financing inflows even as operating cash use increased to $8.3 million. The quarter also brought progress in irradiation testing, patents and fuel-modeling work.
TradingKey
Wed, Aug 5
StoneX Fiscal Q3 2026 Earnings: Net Operating Revenue Rises 47%
StoneX Group’s fiscal Q3 2026 net operating revenue rose 47% year over year to $719.7 million, while diluted EPS increased 85% to $1.00 and net income doubled to $127.9 million. Commercial and Institutional results led the quarter as listed derivatives, physical contracts and securities activity expanded, with the R.J. O’Brien acquisition making a meaningful contribution to listed-derivatives volume and client equity. Self-Directed/Retail remained the main weak spot, and faster variable compensation plus higher corporate funding costs are key items to monitor.
TradingKey
Wed, Aug 5
Carlsmed Q2 2026 Earnings: 57% Revenue Growth Comes With Wider Losses
Carlsmed’s Q2 2026 revenue rose 57% year over year to $18.9 million as aprevo procedure volumes and trained-surgeon adoption increased. Gross margin expanded, but faster growth in research, sales, and administrative spending pushed the GAAP net loss to $10.5 million from $6.8 million. Carlsmed raised full-year 2026 revenue guidance to $74 million–$78 million. Key follow-up issues include expense discipline, the decline in liquid resources, cervical commercialization, and execution around enhanced Medicare reimbursement for inpatient aprevo lumbar procedures beginning in October 2026.
TradingKey
Wed, Aug 5
Clearfield Fiscal Q3 2026 Earnings: Sales Rose 13% as Gross Margin Narrowed
Clearfield’s fiscal Q3 2026 net sales from continuing operations rose 13% to $43.9 million, while diluted EPS increased to $0.22 from $0.16. Gross margin fell to 31.8% from 35.3% after a $2.6 million inventory charge, though lower operating expenses lifted operating income 68% to $2.6 million. The company reduced fiscal 2026 guidance to $151 million-$155 million of net sales and $0.14-$0.21 of EPS as backlog declined, while a post-quarter $22 million hyperscale data center order is expected to begin shipping in early fiscal 2027.
TradingKey
Wed, Aug 5
Kronos Worldwide Q2 2026 earnings: Higher volumes and lower costs restore profitability
Kronos Worldwide’s Q2 2026 revenue rose 13% to $558.1 million, while diluted EPS improved to $0.13 from a loss of $0.08 a year earlier. Net income reached $15.2 million, and TiO2 segment profit increased to $41.0 million from $10.9 million. Higher sales volumes, lower feedstock and production costs, and late-2025 cost reductions drove the earnings recovery, offsetting lower average TiO2 prices and an approximately $12 million negative currency impact on segment profit.
TradingKey
Wed, Aug 5
Weight Watchers Q2 2026 Earnings: Clinical Growth Could Not Offset Behavioral Decline
Weight Watchers (Nasdaq: WW) reported Q2 2026 revenue of $162.3 million, down 14.2% year over year, and diluted EPS of $1.41. Clinical subscription revenue rose 30.4% to $39.9 million, but Behavioral subscription revenue fell 22.7%, leaving total end-of-period subscribers down 21.4%. Adjusted EBITDA was $39.8 million and operating cash flow was $24.3 million. The company reduced term-loan principal by $41.4 million and reaffirmed full-year revenue guidance of $620 million to $635 million and adjusted EBITDA guidance of $105 million to $115 million.
TradingKey
Wed, Aug 5
Crane NXT Q2 2026 Earnings: Acquisitions Drive 22% Sales Growth
Crane NXT’s Q2 2026 sales rose 22.0% year over year to $493.2 million, while GAAP diluted EPS increased to $0.61 from $0.43 and adjusted EPS reached $1.10. Acquisitions contributed 18.4 percentage points of sales growth, compared with 2.8% organic growth. SAT delivered 9.6% organic growth and wider GAAP operating margins, but DTT organic sales fell 3.4% and its adjusted EBITDA margin contracted. Operating cash flow was $86.7 million, and the company raised full-year adjusted EPS guidance to $4.22-$4.42.
TradingKey
Wed, Aug 5
Star Bulk Q2 2026 Earnings: Higher Charter Rates Lift Profit
Star Bulk Carriers’ Q2 2026 earnings showed voyage revenue of $357.4 million, up 44.5% year over year, and diluted EPS of $1.30 versus $0.00. Net income reached $144.9 million, while adjusted EBITDA rose to $184.2 million as the daily TCE rate climbed to $24,486 despite a smaller average fleet. Quarterly operating cash flow was $149.9 million, and the board declared a $0.90-per-share dividend. Higher charter rates drove the quarter, supplemented by bunker-sale and vessel-sale gains.TradingKey
Wed, Aug 5
Clover Health Q2 2026 earnings: Revenue rises 56% as GAAP profit turns positive
Clover Health’s Q2 2026 revenue rose 55.6% to $743.2 million, while diluted EPS swung to $0.05 from a $0.02 loss. GAAP net income reached $28.0 million and adjusted EBITDA climbed 139.2% to $40.9 million as average Medicare Advantage membership grew 48.7% and the insurance BER improved 80 basis points. The company raised full-year revenue, gross profit, adjusted EBITDA and net income guidance, though the annual profit ranges remain close to or below first-half results, making second-half medical costs and operating expenses key items to monitor.
TradingKey
Wed, Aug 5
Akebia Q2 2026 earnings: Vafseo growth did not offset Auryxia decline
Akebia Therapeutics’ Q2 2026 revenue fell 21.4% year over year to $49.1 million, while diluted EPS shifted to a $0.03 loss from breakeven. Vafseo net product revenue rose about 60% to $21.3 million and active patients exceeded 10,500, but Auryxia revenue dropped about 46% to $25.5 million amid generic competition and pricing pressure. Akebia posted an $8.9 million net loss, ended June with $155.5 million in cash, and reported positive interim VOICE trial safety results driven by fewer hospitalizations versus ESA treatment.
TradingKey
Wed, Aug 5
Fluence Q3 FY2026 Earnings: Revenue Rose as Margins Contracted
Fluence Energy’s fiscal Q3 2026 revenue rose 7.9% year over year to $649.8 million, but GAAP gross margin fell to 5.1% from 14.8% and diluted EPS swung to a $0.24 loss. Production delays at new contract manufacturing facilities deferred project deliveries, while new product platform costs and an upfront battery-supply expense weighed on profitability. Despite record order momentum and backlog, Fluence reduced its fiscal 2026 revenue and adjusted EBITDA outlook, making manufacturing execution and cash usage central issues for the remainder of the year.
TradingKey
Wed, Aug 5
Revolution Medicines Q2 2026 Earnings: Daraxonrasib Advances as Spending Rises
Revolution Medicines’ Q2 2026 earnings showed a net loss of $644.4 million, or $3.06 per diluted share, as R&D expense rose to $394.9 million and commercial preparation increased G&A costs. Cash, cash equivalents and marketable securities reached $3.9 billion after April financing and a Royalty Pharma payment. The quarter’s central operating development was FDA acceptance of daraxonrasib’s NDA for previously treated metastatic pancreatic cancer, alongside early lung cancer combination data and updated 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion.
TradingKey
Wed, Aug 5
MannKind Q2 2026 Earnings: Revenue Rises 43% as Costs Drive a Net Loss
MannKind’s Q2 2026 revenue rose 43% year over year to $109.4 million, helped by Furoscix, a 53% increase in collaboration and services revenue, and higher Tyvaso DPI royalties. GAAP diluted EPS was negative $0.06, compared with $0.00 a year earlier, as the company moved to a $19.0 million net loss. SG&A climbed 84% amid Furoscix support and launch preparation for pediatric Afrezza and Furoscix ReadyFlow, while total other expense reached $18.8 million. Cash, cash equivalents and investments totaled about $111 million at quarter-end.
TradingKey
Wed, Aug 5
Featured Tools
Top News
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
Micron vs. SK Hynix: As HBM Demand Continues to Surge, Which Memory Stock Deserves More Attention?
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
The Week Ahead: Fed Minutes, Walmart, Target and Home Depot Earnings to Test US Consumer Resilience
Micron Stock Forecast: Can AI Memory Demand Push MU Above $1,000?
